Biological Half-Life
7-12.8 hours

[1]. D Smit. Anti-infective ophthalmic preparations in general practice, South African Family Practice, 54:4, 302-307.

[2]. Modulating the solubility of sulfacetamide by means of cocrystals†.

Sodium sulfacetamide is a white powder. (NTP, 1992)
Sodium sulfacetamide is a sulfonamide compound in which the nitrogen atom of the sulfonamide is acylated. It has antibacterial, anti-infective, EC 2.5.1.15 (dihydropterolate synthase) inhibitor, and antibacterial drug activities. It is a substituted aniline and N-sulfonylformamide. Its function is similar to sulfonamides. It is the conjugate acid of sodium sulfacetamide (1-).
It is an anti-infective drug, used topically to treat skin infections and orally to treat urinary tract infections.
Sodium sulfacetamide is a sulfonamide antibacterial drug.
Sodium sulfacetamide has been reported in the Chinese honeybee (Apis cerana), and there is relevant data.
Sodium sulfacetamide is a synthetic sulfonylacetamide derivative with antibacterial activity. Sodium sulfacetamide inhibits bacterial folic acid synthesis by competing with p-aminobenzoic acid. It has broad-spectrum antibacterial activity and can be used as a topical anti-infective for skin infections and as an oral medication for urinary tract infections. (NCI04)
An antibacterial drug that can be used topically to treat skin infections and orally to treat urinary tract infections.
See also: sulfacetamide sodium (in salt form); prednisolone acetate; sulfacetamide sodium (note moved to)...see more...

---

Drug Indications
For the treatment of bacterial vaginosis, keratitis, acute conjunctivitis, and blepharitis.
FDA Label

---

Mechanism of Action
Sulfatamide sodium is a competitive inhibitor of bacterial para-aminobenzoic acid (PABA), an essential component for bacterial growth (according to the Woods-Fildes theory). In these organisms, this inhibited response is essential for folic acid synthesis.

---

Pharmacodynamics
Sulfamethoxazole is a sulfonamide antibiotic with antibacterial activity, exhibiting broad-spectrum antibacterial activity against most Gram-positive bacteria and many Gram-negative bacteria. However, many strains of the same species may develop resistance to it. Sulfonamides inhibit bacterial growth by competitively inhibiting para-aminobenzoic acid in the folate metabolic cycle. Bacteria have similar sensitivity to various sulfonamides; resistance to one sulfonamide means resistance to all sulfonamides. Most sulfonamides are readily absorbed orally. However, parenteral administration is challenging due to the strong alkalinity and tissue irritation of soluble sulfonamide salts. Sulfonamides are widely distributed in all tissues. High concentrations can be reached in pleural fluid, peritoneal fluid, synovial fluid, and ocular fluid. Although these drugs are no longer used to treat meningitis, high concentrations remain in the cerebrospinal fluid of patients with meningeal infections. Pus can inhibit their antibacterial activity.

C8H10N2O3S

214.239

214.041

144-80-9

Sulfacetamide-d4;Sulfacetamide-13C6

5320

White to off-white solid powder

1.4±0.1 g/cm3

182-184 °C

0.04mmHg at 25°C

1.584

-0.96

2

4

2

14

299

0

SKIVFJLNDNKQPD-UHFFFAOYSA-N

InChI=1S/C8H10N2O3S/c1-6(11)10-14(12,13)8-4-2-7(9)3-5-8/h2-5H,9H2,1H3,(H,10,11)

N-(4-aminophenyl)sulfonylacetamide

NSC-63871; NSC63871

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Note: This product requires protection from light (avoid light exposure) during transportation and storage.

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

DMSO : ~100 mg/mL (~466.77 mM)

Solubility in Formulation 1: ≥ 2.5 mg/mL (11.67 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

---

Solubility in Formulation 2: ≥ 2.5 mg/mL (11.67 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

---

View More

Solubility in Formulation 3: ≥ 2.5 mg/mL (11.67 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

---

 (Please use freshly prepared in vivo formulations for optimal results.)